Abstract | Advances in genomics, proteomics and molecular pathology have generated many candidate biomarkers with potential clinical value. Their use for cancer staging and personalization of therapy at the time of diagnosis could improve patient care. However, translation from bench to bedside outside of the research setting has proved more difficult than might have been expected. Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality.
The formal TNM staging system 1 (see Online links box), promulgated by the American Joint Committee on Cancer (AJCC), is based almost exclusively on the anatomical extent of disease, which is assessed using a combination of tumour size or depth (T), lymph node spread (N), and presence or absence of metastases (M). Since its inception in 1958, the TNM system has provided a standardized, anatomical basis for staging with several important functions. It provides a basis for prediction of survival, choice of initial treatment, stratification of patients in clinical trials, accurate communication among healthcare providers, and uniform reporting of outcomes. For most tumour types, disease burden and spread have been considered the most reliable predictors of survival and determinants of the type and intensity of therapy to be used. Less often, tumour grade, histological subtype or patient age has been added to TNM staging when the AJCC became convinced that such information would significantly improve the prediction of survival or response to therapy.
The anatomically based TNM staging system is, of course, most useful when local therapies (for example, surgical resection, radiofrequency ablation or regional radiotherapy) provide the only means of cure, as was the case for almost all cancers when the TNM system was established. At that time, the goals ascribed to staging could be accomplished with a single, ordinal parameter of TNM stage. It was prognostically better to be stage I than stage II, better to be stage II than stage III, and so on. The generic dictionary definition of 'stage' has the same implication: it can be defined as 'a degree of advance in a journey' or 'a period or step in a process' .
The anatomically based TNM staging system remains useful for the purposes listed above, but new factors are both complicating the situation and providing new opportunities when it comes to predicting survival and/or selection of therapy. First, individual molecular markers and patterns of markers are successfully subdividing traditional tumour classes into subsets that behave differently from each other. Second, chemotherapeutic and biological agents are more effective and more widely used than when TNM staging was introduced, especially in the adjuvant setting. Third, many new targeted agents such as imatinib (Glivec), gefitinib (Iressa), and cetuximab (Erbitux), as well as older agents (for example, tamoxifen), are effective only if their respective molecular markers are mutated or expressed at sufficient levels. In breast cancer, for example, oestrogen receptor (ER) and HER2/NEU (also known as ERBB2) status have implications for prognosis and therapy that are independent of TNM stage. ER positivity improves prognosis, whatever the stage, and it also makes the tumour a candidate for therapy with a targeted hormonal agent such as tamoxifen or an aromatase inhibitor. Until the advent of trastuzumab (Herceptin), which targets HER2/NEU, HER2/NEU positivity was considered simply as a negative prognostic indicator independent of TNM stage. Increasingly, we can expect to see a 'co-evolution' of biomarkers and their respective targeted therapies.
The examples of ER and HER2/NEU biomarkers raise an immediate question: what should be the relationship between formal TNM staging and newly emerging biomarkers or biomarker combinations? Should the markers be incorporated into the determination of stage or should they be thought of as supplemental features that are outside of the system but serve the same five functions as discussed above for TNM? In this article, we will adopt the broader perspective, thinking of biomarkers as serving the same purposes as TNM staging but not necessarily formally incorporated into that system. We will consider formal TNM stage as one aspect of a snapshot of the cancer's status, most often taken at the time of initial diagnosis but, in principle, taken at any time thereafter.
A second important question is: what can we expect biomarkers to add to traditional staging? An answer is implied in the truism that cancer stage provides only probabilities of the course of disease or outcome for any individual patient. There remains the mysterious heterogeneity of outcomes for patients with cancers of apparently equivalent type, stage and grade. Those differences in outcome may relate, in part, to stochastic events, such as the time at which a single cancer cell happens to undergo all of the steps necessary for successful metastasis, or they may relate to factors that can be reasonably well understood at a deterministic level. Even if molecular markers cannot eliminate the stochastic uncertainties and enable us to predict outcome definitively, they will almost certainly increase our accuracy at subclassifying patients and their cancers. We can expect that biomarkers will help us towards more personalized medicine. Again, the example of ER status in breast cancer is paradigmatic.
Although the incorporation of biomarkers into TNM staging has been a subject of considerable discussion by both the TNM committees and the broader biomedical community, no formal consensus has been reached. We contend that uncertainties about the role of biomarkers contribute to a fundamental paradox: despite the many current and emerging markers available in the clinical research setting, few have been integrated into clinical practice 2 . In this review, we will address the current use of both US Food and Drug Administration (FDA)-approved and other biomarkers available for use in clinical oncology, with special emphasis on staging, grading, and selection of therapy at the time of diagnosis. We will then discuss the types of biomarkers that are emerging for use at clinical research centres. Finally, we will consider practical factors such as clinical validation, regulatory approval and economics that seem to be limiting the integration of biomarkers into clinical practice.
The biomarker paradox
Although fewer than 10% of cancers can be traced to Mendelian inheritance, the ability of malignant cells to proliferate and metastasize can be ascribed to genetic alterations. Those alterations typically lead to activation • There is a dilemma in TNM staging: frequent revisions to include new biomarkers would undermine the value conferred by the stability and universality of TNM, but a static formulation of TNM risks falling behind the state of the art in diagnostic techniques, biological concepts and biomarkers.
• Biomarkers initially considered for cancer screening or risk assessment might also prove useful for cancer staging or grading.
• A biomarker for use in staging or grading need not be as specific as it must be for screening, early detection or risk assessment.
• As molecularly targeted cancer therapeutics become more common, assessing the intended target will more often be deemed necessary for prediction of clinical response, independent of TNM stage. Targeted therapies and their associated biomarkers will often 'co-evolve' .
• The ideal biomarker assay for staging should be sensitive, specific, cost-effective, fast, and robust against interoperator and inter-institutional variability. It must also demonstrate clinical value beyond that of the other types of information that are already available at the time of diagnosis.
• Biomarker candidates must undergo clinical validation before receiving US Food and Drug Administration approval. For most candidate markers, that process is just beginning.
• Despite all of the potentially useful biomarkers -for example, those identified from microarray or mass spectrometry studies -almost none have been incorporated into formal TNM staging.
© 2005 Nature Publishing Group 6 . Similarly, biomarkers have been reported to distinguish primary head and neck squamous cell carcinoma (HNSCC) from metastatic lung squamous cell carcinoma (SCC) 7 , to determine the site of origin for HNSCC of unknown primary location 8 and to track genetic mutations that occur with the progression of that tumour 9 .
Grade. Each anatomical site has its own histological grading system, designed to classify malignancies by degree of differentiation. Low-grade, well-differentiated tumours are usually less aggressive and more favourable in prognosis than high-grade tumours, which tend to grow faster and metastasize earlier. However, tumour grade is included in formal TNM staging only when intimately linked to prognosis, as it is for soft-tissue sarcomas, prostate cancer and primary brain malignancies. Assignment of grade is inherently subjective and dependent on the skill and experience of the reviewing pathologist, but several reports indicate that biomarker patterns can correctly score tumours according to their pathologist-assigned grades 10 . COMPUTERAIDED DIAGNOSTIC SYSTEMS (CAD systems) have been approved by the FDA for preliminary grading of cervical smears (that is, Pap smears) 11 and for assisted interpretation of radiological images such as screening mammograms 12 , computerized tomography (CT) scans 13 and standard X-ray films 14 . CADs are generally designed to make routine distinctions, giving the pathologist time to focus on difficult diagnostic problems. The acceptance of CADs has been accelerated by the fact that there had previously been extensive and rigorous standardization and quality control of the underlying imaging technologies (for example, mammograms and chest X-rays). A biomarker constructed from a pattern of individual markers that, when evaluated together, can be used for risk assessment, screening, diagnosis, staging, selection of therapy and/or monitoring of therapy. The specific markers that make up the pattern may or may not have been identified.
SINGLEPHOTON EMISSION COMPUTED TOMOGRAPHY
Imaging technology in which a photon detector array is rotated around the body to acquire data from many angles following the injection of a γ-emitting radionuclide.
The absence of analogous standardization of biomarker platforms is an important practical problem.
If the problems can be overcome, however, the addition of either individual or PATTERNBASED BIOMARKERS in the assessment of histological grade could increase the utility of grading for predicting response to therapy. That would be a natural extension of current practice as pathologists already have considerable experience using at least a few markers (for example, ER, the progesterone receptor (PR) and HER2/NEU) in related contexts.
Stage. The AJCC, in collaboration with the TNM Committee of the International Union Against Cancer (UICC), has defined staging criteria for most anatomical sites 15 . T, N and M are determined separately and then grouped, usually to classify the cancer into one of four main stages (stages I-IV) and subdivisions thereof. Breast cancer staging, for example, distils 30 possible TNM combinations into 5 main prognostic stages 15 . Clinical staging, which is primarily used to guide initial therapy, integrates information from physical examination with data such as those from standard X-ray, CT, MRI, PET, endoscopic examination, biopsy, and surgical exploration. Pathological staging on the basis of surgical specimens, if acquired, complements clinical staging with a precise determination of the extent of disease and additional histological information.
Increasingly, imaging agents targeted at biomarkers are being used for anatomical localization. The most common are radioisotopes, detected by standard nuclear medicine imaging, by SINGLEPHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) or by PET. Also under study are fluorescent molecules, which are detected by optical imaging, and paramagnetic particles for enhancing MRI. The target can be any marker that delineates the cancer or its metabolism. Some tumours (for example, carcinoid, phaeochromocytoma, and cancers of the prostate, thyroid and colon) can be targeted by specific radiolabelled ligands. Carcinoid tumours, for example, are often localized using a radiolabelled analogue of octreotide (111-indium pentetreotide), which avidly binds to the somatostatin receptor, a protein commonly overexpressed in those tumours. Nuclear medicine-based imaging modalities are also clinically useful for evaluating tumour-related phenomena including angiogenesis 16 , apoptosis 17, 18 , proliferation 19 , metabolism 20, 21 , hypoxia 22 and drug resistance (such as P-glycoprotein function) 23 . Molecularly targeted functional imaging has enormous potential for staging, as it does for other aspects of cancer diagnosis and management, and it might also be easier than serum biomarkers to integrate into clinical TNM staging, given its anatomical basis.
For most solid tumours, the primary purpose of anatomy-based staging is to discern the probability of localized, as opposed to metastatic, disease. That crucial distinction, in considerable part, predicts survival and guides the choice of initial therapy. Anatomy-based staging, however, provides only part of the answer. A more precise picture can often be obtained by incorporating tumour grade and histological subtype. The role that biomarkers can play is exemplified by HER2/NEU, which is associated with an aggressive phenotype, decreased patient survival 24, 25 and response to trastuzumab.
Acknowledging the potential importance of serum-derived biomarkers for staging, the AJCC incorporated the first such markers -serum α-fetoprotein (AFP), human chorionic gonadotropin-β (β-HCG, also known as CGB) and lactate dehydrogenase (LDH) for testicular cancer -into the TNM system. That necessarily cautious shift in the staging guidelines reflects the increased scientific evidence, at least for several cancer types, of more accurate prognosis with the addition of factors independent of anatomy and histological grade. However, as stated previously, most cancers are still exclusively staged by anatomic criteria, with a few exceptions (for example, sarcomas and malignancies of the thyroid, prostate, brain and testicle).
The AJCC sometimes informally recommends supplementation of TNM staging with information about tumour grade, histological subtype or relevant immunohistochemical (IHC) markers when they have prognostic or therapeutic value. Suggested supplementary parameters for breast cancer, for example, include those with proven value in predicting response to therapy (ER, PR and HER2/NEU receptor status). IHC or reverse transcription-PCR (RT-PCR) evaluation of sentinel lymph nodes is occasionally performed in clinical trials when microscopic examination is negative and, if obtained, is included as supplemental information in AJCC breast cancer staging. However, most supplementary markers have not been clinically validated, and the significance of lymph nodes that are negative by standard pathological staining with haematoxylin and eosin but positive by IHC or PCR remains unclear. The TNM system classifies nodes with cancer cell clumps less than 0.2 mm in diameter as nodenegative, even when RT-PCR detects tumour cells. Such small clumps of cancer cells usually lack markers of proliferation and rarely induce a stromal reaction that indicates tumour implantation or growth 15, 26 . Any updating of a system like TNM can have advantages but also imposes a price. Ideally, one would like to incorporate the latest supportable medical science, including new biomarkers. However, the relatively static, stable character of the system enhances its utility for stratifying patients in clinical trials, for communication among physicians and for standardizing the classification of tumours among institutions and nations. If the staging criteria were changing more often, it would be difficult, for example, to determine whether earlier clinical research was pertinent to current or future patients who are, or will be, staged differently. Furthermore, information supplemental to TNM is often incomplete or sporadically noted in medical records because it is not formally part of the staging process. Adoption of a formal 'augmented' staging system that included both a relatively static TNM component (updated occasionally) and a dynamic supplemental component (revised at the pace of scientific discovery) could perhaps resolve that paradox and allow new markers to be evaluated formally without undermining the value of anatomical staging.
Prognosis and treatment selection. Tumour classification, stage and sometimes grade are used to assess prognosis. However, as noted above, there would be a cost if formal cancer staging incorporated every other parameter able to improve prognosis. Furthermore, stratification in clinical trials using all possible TNM combinations would be impractical, given limitations in patient participation and resources. Addition of markers could similarly fragment the staging process, thereby limiting its utility. More information is generally better than less information, but the advantages must be weighed against those of a stable classification with relatively few categories. Biomarker expression often supplants or complements tumour classification, stage and grade when biologically targeted therapeutics are under consideration. Prominent examples include CD20 positivity for treatment of lymphomas with rituximab, HER2/NEU positivity for treatment of breast cancer with trastuzumab 27 , BCR-ABL translocation for treatment of chronic myelogenous leukaemia (CML) with imatinib, and KIT or platelet-derived growth factor receptor-α (PDGFRA) positivity for treatment of gastrointestinal stromal tumours (GIST) with imatinib 28 . As previously discussed, ER positivity or PR positivity is a prerequisite for treatment with tamoxifen or aromatase inhibitors. Similarly, somatic mutations in the tyrosine-kinase domain of the epidermal growth factor receptor (EGFR) have recently been shown to predict a greater efficacy of gefitinib in patients with nonsmall-cell lung cancer (NSCLC) 29, 30 . Some of those markers are FDA-approved and in widespread clinical use (see TABLE 1); others have been assessed only in the research setting. For example, ER, PR and HER2/NEU status are routinely determined for breast cancer, whereas EGFR mutations are usually assessed only in clinical trials. Outside of such trials, patients with NSCLC are often given EGFRantagonists, such as gefitinib, as salvage therapy on an empirical basis without marker studies, especially if they are more likely to have the mutation (that is, patients who are female, never-smokers, diagnosed with adenocarcinoma, or Asian) 31 . Both prognosis and prediction of response are necessary for the selection of neoadjuvant or adjuvant chemotherapy. Tissue classification, TNM staging, molecular biomarkers, grade and other factors might be used in combination for that purpose. The combinations of variables might not be easy to analyse manually, but computer DECISION SUPPORT SYSTEMS (DSS) can make the assessments automatically. For example, Adjuvant Online (see Online links box), a DSS used for breast cancer, estimates 10-year cancer recurrence and survival for women, taking into account their predicted response to adjuvant chemotherapy 32 . Markers can also be used to avoid idiosyncratic drug toxicity such as the sustained, life-threatening leukocyte suppression seen when mercaptopurine is given to leukaemia patients with homozygous mutations of the thiopurine methyltransferase (TPMT) gene 33, 34 . Biomarkers traditionally used for risk assessment and screening are also available to enhance cancer staging, refine prognosis and estimate response to biological therapy, as summarized in BOX 1 
3. An important point: characteristics that suit a molecular marker for one application might not do so for another. For example, a marker to be used in screening the general population must have an extremely high specificity to minimize false positives that necessitate costly or invasive follow-up studies and scare patients and their families needlessly. The same marker need not be so specific if used for high-risk populations and can be even less so once a cancer has been detected. The arguments about use of PSA for screening continue, but its value in monitoring diagnosed prostate cancer or its treatment would be hard to dispute.
Biomarkers on the horizon
Genomic and proteomic technologies have significantly increased the number of potential DNA, RNA and protein biomarkers under study. Here, we will focus on several types with promise for staging. DNA biomarkers. Circulating DNA and tumour cells were among the first markers evaluated for cancer staging. Increased serum DNA concentrations are associated with cancer (principally metastatic cancer) and with other conditions such as sepsis and autoimmune disease 35, 36 . A number of studies suggest circulating tumour cells in the blood [37] [38] [39] or bone marrow 40, 41 as indicators of systemic metastasis, but the clinical sample sizes have been small and the long-term survival benefit remains to be assessed 42 . Mutations in oncogenes, tumour-suppressor genes, and mismatch-repair genes can serve as DNA biomarkers. For instance, mutations in the oncogene KRAS predict metastatic spread in various tumour types 43 , and there are mutations in the gene that encodes the tumour suppressor p53 in more than half of sporadic cancers 44, 45 . Germline inheritance of a TP53 mutation (Li-Fraumeni syndrome) confers a risk of developing many of the same cancers. Mutations in other cancer-related genes, such as the RAS oncogene or the tumour-suppressor genes CDKN2A (cyclin-dependent kinase inhibitor A, which encodes p16INK4A), APC (the adenomatous
Box 1 | New applications for established biomarkers
Biomarkers can play roles before cancer diagnosis (in risk assessment and screening), at diagnosis (as discussed in the main text) and after diagnosis (in monitoring therapy, selecting additional therapy and detecting recurrence) (FIG. 3) . This review focuses on applications at the time of diagnosis, but markers that are currently considered for risk assessment or screening may also prove useful in cancer staging or prediction of response at the time of diagnosis. For example, the BRCA1 (breast cancer 1) gene can be used in breast cancer, both for risk assessment and as a predictor of 10-year survival 118 . For patients with HIV/AIDS, the viral load and CD4-positive T-cell count predict the likelihood of acquiring an AIDS-related cancer and the probability that such a tumour will respond to highly active anti-retroviral therapy (HAART).
For risk assessment and screening, a marker must generally be inexpensive, highly specific and minimally invasive. Those requirements do not necessarily apply to markers for staging or grading. As noted in the text, markers considered infeasible for screening because they would yield too many false positives may still be useful after diagnosis. For example, serum CEA (carcinoembryonic antigen) is increased in colon, breast and lung cancer, but also in many benign conditions. It is, in that sense, non-specific, but increases in the context of known colon cancer strongly suggest recurrence of that malignancy. Similarly, although AFP (α-fetoprotein) and β-HCG (human chorionic gonadotropin-β) can be increased for many reasons, their reliability in assessing testicular cancer burden following diagnosis accounts for their integration into staging. PSA (prostate-specific antigen), cancer antigen (CA) 125, CA19-9, and other, similar markers [119] [120] [121] [122] [123] [124] polyposis coli gene) and RB1 (the retinoblastoma gene), also have potential as markers for prognosis or selection of therapy. As discussed previously, the efficacy of anti-EGFR agents such as gefitinib might depend on specific EGFR point mutations. Second EGFR mutations acquired in patients with NSCLC during therapy have, in some cases, been reported to confer resistance on a previously sensitive tumour, and might therefore be useful prognostic biomarkers 46 . Epigenetic regulation of transcription and translation can also be important in carcinogenesis. Histone deacetylation, lysine-specific histone-H3 methylation, and promoter region CpG methylation can function through transcriptional abrogation of tumour-suppressor genes (for example, CDKN2A, TP53, APC or the breast cancer 1 gene, BRCA1) [47] [48] [49] [50] or DNA mismatch-repair genes (for example, MLH1 or the O 6 -methyl-guanine-DNA methyltransferase gene, MGMT). They can also function through effects on apoptosis, invasion and the cell cycle 50, 51 . Gene silencing by CpG methylation has received the most attention, partly because sensitive methods of measurement have become available 36, 51, 52 . It has been reported, for example, that differences in methylation can distinguish prostate cancer from benign prostatic hyperplasia 53 . Shedding of hypermethylated DNA into saliva from oral malignancies 54, 55 , into sputum 56 or bronchoalveolar lavage fluid 57 from lung cancer, and into serum from patients with lung 58, 59 , bladder 60 or colorectal cancer 61, 62 , has also been demonstrated.
Pharmacogenomic effects of methylation silencing, with implications for choice of therapy, have also been shown. For example, promoter region methylation of MGMT, an enzyme that reverses 5′-guanine alkylation, predicts the response or resistance of gliomas to nitrosourea alkylating agents 63, 64 . To our knowledge, epigenetic factors have not yet been used in formal staging, but their application to predict response to treatment can be expected in the future, particularly given the development of DNA-demethylating drugs such as 5-azacytidine 65 and zebularine 66 , as well as novel histone-deacetylase inhibitors such as depsipeptide (FK228) 67, 68 . Other potential DNA biomarkers, including SNPs, mitochondrial DNA markers and oncoviral markers, are discussed in BOX 2. RNA biomarkers. Whereas most DNA markers are evaluated individually, many high-throughput technologies have been developed to assess mRNA expression comprehensively. Among them are Affymetrix and NimbleGen arrays that are produced by light-directed in situ synthesis of oligonucleotides, Rosetta-Agilent ink-jet-printed arrays, DIFFERENTIAL DISPLAY, SERIAL ANALYSIS OF GENE EXPRESSION (SAGE), and BEADBASED METHODS [69] [70] [71] . Quantitative real-time RT-PCR is generally considered the 'gold standard' against which other methods are validated, and it can now be performed at relatively high-throughput -for example, by using MICROFLUIDIC cards 72 . Most RNA-based biomarkers undergoing clinical evaluation consist of multi-gene molecular patterns or 'fingerprints' . Although such patterns can be more accurate than single-molecule markers, choosing which genes to include in the pattern adds an additional layer of statistical complexity, prompting new developments in biostatistics, bioinformatics and data visualization. Molecular markers and their patterns have been analysed by various SUPERVISED ALGORITHMS, most prominently by double hierarchical clustering methods that lead to colour-coded 'clustered image maps' (CIMs). We introduced CIMs in the early 1990s to illuminate patterns of similarity and difference in high-throughput DNA, mRNA, protein and pharmacological profiling studies 73 , and they have since become the most familiar visual icon of 'postgenomic' biology. Various supervised statistical and machine-learning methods for classifying tumours have also been introduced. Both the experimental technologies and the methods of analysis have been reviewed extensively elsewhere 74, 75 . Pattern-based RNA-expression analysis of clinical breast cancers has identified previously unknown molecular subtypes that are associated with differences in survival [76] [77] [78] . That analysis has also provided increased prognostic capability 79, 80 , predicted response to neoadjuvant therapy 81, 82 , predicted the likelihood of metastasis in lymph-node negative patients 83 and correctly predicted tumour grade from LASERCAPTURE MICRODISSECTED specimens. The transcript levels of enzymes important for drug metabolism have been used preclinically to predict the response to chemotherapy in lung 84 and colon 85 cancers. Similar approaches have led to novel discoveries for other cancers, including melanoma 86, 87 , leukaemias, lymphomas [88] [89] [90] , and carcinomas of the lung 87, 91 , prostate 92 and colon 93 . Such cancer 'snapshots' taken at the time of diagnosis can be expected to further the goals of cancer staging. Extensive validation studies will be required, however, to move those developments from clinical research to standard practice in staging. Several companies have attempted to do so and have made their RT-PCRbased gene signatures available to the public for use in predicting survival. However, these and other RNA-based markers have not yet undergone rigorous, prospective clinical validation, and they have not been approved by the FDA.
Protein biomarkers. As shown in TABLE 1 and mentioned before, all but a handful of the FDA-approved cancer biomarkers in clinical use are single proteins, and most are serum-derived. AFP, β-HCG and LDH are used in the AJCC system to stage testicular cancer. Other proteins, although not formally used for staging, are important for prognosis and selection of therapy. For example, the expression of HER2/NEU and CYTOKERATINS can be used to refine the prognosis of breast cancers. HER2/NEU, EGFR and KIT are used clinically to predict if breast cancers, colon cancers or GISTs will respond to trastuzumab, cetuximab or imatinib, respectively. Similarly, expression of ER or PR is necessary for hormonal therapies to be effective against breast cancer.
Just as pattern-based RNA biomarkers frequently outperform single RNA markers in tumour classification, prognosis or prediction of response to therapy, protein-based 'fingerprints' may outperform individual protein markers. Technologies such as differential in-gel electrophoresis (DIGE) 94 , two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and multidimensional proteinidentification technology (MudPIT) can be used for higher-throughput profiling with microgram quantities of protein. Other high-throughput technologies, such as the REVERSEPHASE MICROARRAY 6, 95, 96 (FIG. 2) and surface-enhanced laser desorption ionization time-of-flight (SELDI-TOF) mass spectrometry, are more sensitive (in the femtomolar range) and can cover more of the 12 orders of magnitude range of serum-protein expression levels 5, 75, 97, 98 [125] [126] [127] [128] [129] [130] [131] , perhaps as few as 10% of the SNPs will have to be sequenced for useful haplotype-based risk assessment. Genome-wide SNP analysis has been reported 132, 133 , but SNPs are not currently used for formal cancer staging or grading. 
Oncoviral markers

, kidney
142 and testis 141, 143 . However, despite the promise of mtDNA for cancer screening, its value for tumour classification, staging or grading has yet to be determined. Protein quantity by itself might not be the salient marker parameter. Protein function is instead often dependent on phosphorylation, glycosylation, other post-translational modifications, location in the cell and/or the location in the tissue. The important phosphorylation-dependent signalling cascades can be assessed, for example, using reverse-phase arrays 6, 95, 96 . Laser-capture microdissection and similar technologies can be used to obtain DNA, mRNA or protein from precise locations within a tumour and thereby distinguish markers inherent to the malignant cells from those in other cell types within the tumour. Microdissection has enhanced expression profiling of breast 10, 106, 107 , ovarian 108 , oral 109 and prostate 110 cancers, as well as other cancer types 97 .
Biomarker validation
Regardless of their intended use, scientifically vetted biomarkers must clear a number of practical hurdles before they can be considered for clinical practice (FIG. 4) . Five conceptual phases of biomarker development have been proposed: preclinical exploratory (I), clinical assay and validation (II), retrospective longitudinal (III), prospective screening (IV) and cancer control (V) 111, 112 . . Furthermore, there should be reliable reproducibility within and among laboratories. However, those ideal conditions rarely apply. There is widespread recognition that standards and standardization are required, but consensus is hard to achieve. There is also the continuing concern that many of the salient technologies are not yet mature enough for standard operating procedures to be set in stone.
It is beyond the scope of this article to review methods of data analysis for identifying and validating biomarkers, but a few cautionary words might be in order. The multivariate statistical and machinelearning algorithms used to define markers are prone to OVERFITTING. The more flexible and non-linear the algorithm, the greater the danger. An algorithm may perform well on the original sample set (that is, the training set) but fail when applied to independent validation samples. Careful validation is especially important for patterns of markers 129 , and the NCI's Early Detection Research Network (EDRN), in collaboration with the National Institute of Standards and Technology, continues to support "coordination among biomarker development laboratories, biomarker validation laboratories, clinical repositories, and population-screening programs" 111 . Analogous joint efforts between industry and academia combine the strengths of academic institutions (including access to archived clinical specimens and clinical study patients) with those of industry (including high-throughput drug and biomarker discovery/development programmes). The price of multi-institution studies, of course, is that they are harder to manage and coordinate. A biomarker is first identified, then evaluated for a particular clinical indication. Analytical and clinical validations must be performed before submission for US Food and Drug Administration (FDA) approval. Alternatively, the marker might bypass the FDA approval process if it is to be used for 'research purposes only'. Once a marker is FDA-approved, the Center for Medicaid and Medicare Services (CMS) might determine that it is 'reasonable and necessary' for improved patient care and, therefore, reimbursable. Because CMS decisions indirectly influence coverage by private insurance carriers, a marker is not widely used in the clinic unless all of the steps in the process have been completed. Regulatory process. We will focus here on the situation in the United States, recognizing that similar issues arise elsewhere as well. As a result of the medical device amendments of 1976, the FDA has been charged with regulating in vitro diagnostic devices (IVDs), including tumour markers, to ensure their 'safety' and 'effectiveness' as defined in the Code of Federal Regulations 114, 115 . The 'safety and effectiveness' of an IVD refers to the consequences expected from reliance on it to make 'clinically significant' diagnostic or treatment decisions 115 . Unless already used to detect recurrent disease or monitor the effectiveness of therapy, most tumour markers require clinical studies to support a manufacturer's claim of effectiveness and safety before they receive FDA approval for clinical laboratory use. In analogy with an investigational new drug (IND) application, which is required before trials begin with a novel agent, a pre-investigational device exemption (IDE) allows trials that are designed to evaluate a new IVD 116 . The arduous, expensive clinical validation process is predicated on a thorough analytical validation of all reagents and machines used.
A somewhat less onerous path for transition from laboratory to clinic is provided by classification as an ASR. That designation allows biomarkers to be used in an institution's in-house clinical laboratory for restricted 'research-only purposes' . Rather than the FDA, the Center for Medicaid and Medicare Services (CMS), in accordance with the clinical laboratory improvement amendments of 1988, monitors both the manufacture and laboratory use of ASRs. CMS oversight helps to ensure that biomarkers classified as ASRs are accurate, safe for patients and laboratory personnel, and available for research use while their potential clinical utility is being explored before submission for FDA-approval.
Financial resources.
A final hurdle to the widespread integration of biomarkers is their medical economics. The escalation of medical costs in the United States has focused the nation's attention on cost-benefit analysis -an often difficult and controversial hurdle to overcome, even for established biomarkers such as PSA. Some prospective benefits, such as refined prognostic accuracy and increased patient comfort, are difficult to place a value on objectively. Others, such as predicted responses to treatment with biologically targeted therapies, are more easily quantified.
In the United States, the CMS determines whether the government, through Medicare or Medicaid, will reimburse laboratories for IVD testing using a 'reasonable and necessary' standard. That decision trickles down to private insurers because most echo Medicare's reimbursement practices. Tumour marker IVDs may, of course, be used without reimbursement, but they are expensive and unlikely to be applied widely without strong evidence of clinical benefit. For that reason, most markers are used only in the research setting until approved by the FDA and supported by insurers. Similarly, markers used in other countries must successfully overcome their respective regulatory and financial hurdles before being widely used for patient care.
Conclusion
New high-throughput 'omic' technologies 144, 145 in postgenomic biology have yielded many potential biomarkers and biomarker patterns, some of which may prove useful for staging and grading cancers 117 . The potential is enormous. Few markers, however, have so far been integrated into clinical practice. Metaphorically speaking, the 'water' is everywhere, but little is yet ready to drink. We have considered a number of the readily definable reasons here. Not so easy to assess or quantify are many of the practical issues, such as the queasiness of pharmaceutical companies about fractionation of their markets and their medico-legal fear of generating and possessing too much information that could later be used to their detriment. Furthermore, acceptance and adoption by practicing physicians and patients can take time. But as therapies become increasingly target specific, biomarkers will inevitably develop in tandem to play greater roles in staging, grading, and selection of therapy. The flood of potential biomarkers is opening the way to a more individualized practice of oncology, although the practical problems are many and difficult.
